Clinical Trial Detail

NCT ID NCT03093272
Title A Study of Docetaxel + ARN-509 in Castration-Resistant Prostate Cancer
Recruitment Terminated
Gender male
Phase Phase II
Variant Requirements No
Sponsors Dana-Farber Cancer Institute
Indications

prostate adenocarcinoma

Therapies

Leuprolide

Prednisone

Apalutamide + Docetaxel

Age Groups: adult senior

No variant requirements are available.